M&A / Deals Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn Pharmaceutical Business ReviewThe value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments.Rare DiseaseRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) Pharmaceutical Business Review The value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments. Rare Disease Read full story Post navigation Previous: ASCO26: AZ triplet makes waves in frontline liver cancerNext: ASCO26: Symptom-tracking app helps advanced cancer patients Related Stories M&A / Deals Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology pharminent September 2, 2026 M&A / Deals Lilly adds to immune drug pipeline with $2.9B Merida buyout pharminent August 31, 2026 M&A / Deals Acquisitive Lilly offers $2.88bn for Merida Bio pharminent August 31, 2026